Spots Global Cancer Trial Database for Study to Evaluate the Safety and Pharmacokinetics of MEDI9090 in Subjects With Advanced Solid Tumors
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Trial Identification
Brief Title: Study to Evaluate the Safety and Pharmacokinetics of MEDI9090 in Subjects With Advanced Solid Tumors
Official Title: A Phase 1 Study to Evaluate the Safety and Pharmacokinetics of MEDI9090 in Subjects With Advanced Solid Tumors
Study ID: NCT02900157
Conditions
Study Description
Brief Summary: This is an open-label, study of MEDI9090 to evaluate the safety, tolerability, PK, immunogenicity, and antitumor activity of MEDI9090 in adult subjects with advanced solid tumors.
Detailed Description:
Eligibility
Minimum Age: 18 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: ALL
Healthy Volunteers: No
Locations
Research Site, Scottsdale, Arizona, United States
Research Site, Los Angeles, California, United States
Research Site, Denver, Colorado, United States
Research Site, Huntersville, North Carolina, United States
Research Site, San Antonio, Texas, United States
Research Site, Koto-ku, , Japan
Research Site, Sapporo-shi, , Japan
Research Site, Sunto-gun, , Japan
Contact Details
Name: MedImmune LLC
Affiliation: MedImmune LLC
Role: STUDY_DIRECTOR
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
